Ibrutinib, a pyrazolopyrimidine derivative, is a Bruton’s tyrosine kinase (BTK) inhibitor useful for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The gene discussed is BTK; the disease is mantle cell lymphoma.